CGAT: a Vital Instrument in the Prognostic Toolbox for AML by Frost, Sophia
July 20, 2015 SCIENCE SPOTLIGHT 
 
1 Volume 5, Issue 7 | Fred Hutchinson Cancer Research Center 
 
CGAT: a Vital Instrument in the Prognostic 
Toolbox for AML 
July 20, 2015 
     SHL Frost 
 
Kaplan-Meier curves showing the 
prognostic impact of cnLOH. Blue lines 
in A (% relapse after CR) and C (% 
survival) represent cnLOH; black lines 
represent no cnLOH. In B (% relapse 
after CR) and D (% survival), blue and 
black lines represent 13q cnLOH and 
no 13q cnLOH, respectively. 
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Normally, human cells contain two copies of each chromosome; one each from the mother and the 
father. In some cases, whole chromosomes or segments of chromosomes may appear to be from 
only one parent; although the copy numbers remain normal, the genetic variability is lost. This is 
called copy-neutral loss of heterozygosity (cnLOH), and can be identified using chromosome 
genomic array testing (CGAT). Detection of chromosomal DNA irregularities using genomic 
microarray techniques is generally important for diagnosis and prognosis of patients with acute 
myeloid leukemia (AML), but the World Health Organization does not currently include cnLOH 
among its criteria for classifying tumors of hematopoietic and lymphoid tissue. To elucidate its 
prognostic significance, Dr. Min Fang from Fred Hutch's Clinical Transplant Research Program 
(Clinical Research Division) initiated a study to correlate acquired clonal cnLOH in AML patients - 
which relatively often display the abnormality - with various covariates, mutations, risk classification, 
and outcome after treatment. The results were recently published in Cancer, with cytogenetics 
technologist Christine Gronseth at the Seattle Cancer Care Alliance (SCCA) as first author. 
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A total of 112 AML patients who underwent chromosome genomic array testing (CGAT) at the SCCA 
were included in the study. DNA was taken from blood or bone marrow samples and analyzed using 
a high-density microarray, including detection of single-nucleotide polymorphisms. Of the 112 
patients, 40 had cnLOH; the remaining 72 comprised the control group. In the cnLOH cohort, 33 of 
40 had cnLOH involving a single chromosome arm; cnLOH involving 2, 3, and 4 chromosome arms 
were found in 5, 1, and 1 patient(s), respectively. The most common sites of cnLOH were at 11p and 
13q in this patient population. 
Overall, cnLOH did not significantly impact the clinical remission rate (60 % in patients with cnLOH, 
and 74 % in patients without; p = 0.14). On the other hand, presence of the abnormality was clearly 
correlated with disease recurrence (1.87-fold higher in patients with cnLOH; p = 0.02), with a striking 
6.64-fold higher relapse rate in patients with cnLOH in chromosome 13q (p = 0.002), also after 
adjustment for age, cytogenetics, and secondary versus de novo (without association to previous 
therapy) AML. The risk of death was consequently increased by a factor of 3.45 (p = 0.05) in this 
population. Further, the CGAT findings were correlated with results from molecular testing for gene 
mutations. Fms-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation data was 
available for 78 of the 112 patients, and the mutation was clearly associated with cnLOH in 13q. Six 
patients with 13q cnLOH were tested for FLT3; all of them were positive for FLT3-ITD. Patients with 
FLT3-ITD mutation with 13q cnLOH had shorter duration of remission and shorter overall survival 
than patients with the FLT3 mutation without 13q cnLOH (p < 0.01). 
The study is the first to demonstrate an association between a complex CGAT result (at least three 
CGAT abnormalities) and poor outcome, analogous to that of a complex karyotype (at least three 
clonal abnormalities) as determined using conventional cytogenetics. Importantly, 13 % of the 
patients had abnormalities detected by CGAT that would not have been found using standard 
techniques only. "CnLOH cannot be detected by conventional methods," Dr. Fang said. "Some of 
our providers have not yet fully embraced the usefulness of CGAT and are unsure about whether 
CGAT-identified abnormalities are equally significant as those detected by conventional cytogenetics 
and FISH," she continued, emphasizing her hope that this paper will highlight these concerns. 
According to the authors, CGAT may be most useful for AML patients with an intermediate 
cytogenetic risk, from the perspective of clinical practice. The risk is enriched in patients with normal 
cytogenetics but abnormal CGAT - a patient population with particularly uncertain prognosis, for 
which the benefits of allogeneic hematopoietic cell transplantation are difficult to predict, in relation to 
the treatment-associated risks. Identifying prognostic factors for this patient population is one of the 
future goals for the investigators, Christine Gronseth explained. 
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Thus, the investigators found their answers: cnLOH has, indeed, prognostic significance in AML 
patients, and CGAT is useful for improving diagnosis and care. "Establishing the clinical utility of 
acquired clonal cnLOH in AML patients is an important key to personalized medicine," Gronseth 
said. "The detection of cnLOH is helpful not only to establish the patients' prognosis, but also to 
follow the disease status and progression," she added. 
Patients with cnLOH were few in the current study, and the prognostic effect of aberrations in 
individual chromosomes was therefore not easily quantifiable. The researchers are keen on 
continuing the investigations, and Gronseth staked out the future direction: "We have already begun 
analysis of cnLOH on specific chromosome arms and hope to conduct a multi-institutional 
collaboration to increase the study size." 
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